Challenges for Addiction Treatment Across the Continuum of Care (NAM - ASAM Collaboration)
- Non-Member - Free!
- Regular Member - Free!
- Retired - Free!
- Early Career Physician - Free!
- Resident - Free!
- Student - Free!
- Associate - Free!
- ASAM Staff - Free!
- International Member - Free!
- Emeritus Member - Free!
- Provisional Member - Free!
- Fellow Member - Free!
- Honorary Member - Free!
- CRT Member - Free!
Challenges for Addiction Treatment across the Continuum of Care (NAM-ASAM)
As the leader in developing clinical guidelines and standards in addiction medicine, ASAM takes its responsibility very seriously. Many providers and programs are urgently working to mitigate risks related to COVID-19. This joint NAM-ASAM webinar recording provides an overview of increasing COVID-19 resources and discusses evolving guidance to inform your practices during the pandemic.
This session was recorded as part of the ASAM-NAM webinar series, "Supporting Addiction Treatment During COVID-10" and this session is part 2 of the 3 part series.
Original Recording Information
Date: Friday, May 22, 2020
Time: 2:30 pm ET / 1:30 pm CT/ 11:30 am PT
- Kelly Clark, MD, MBA
- Margaret Jarvis, MD, DFASAM
- Melissa Weimer, DO, MCR, FASAM
- Vincent G. Nelson, MD, MBA, FASA
By completing this session, you will be able to:
• Discuss unique challenges to substance use treatment providers and patients during the COVID-19 pandemic.
• Recognize patient-centered strategies for maintaining substance use treatments and services in a variety of settings including Opioid Treatment Programs (OTP), Office Based Opioid Treatment (OBOT), residential treatment programs, and acute care settings.
• Describe effective protocols for infection mitigation in outpatient and residential settings.
• Identify strategies to ensure effective protocols for coordination between different care settings during the COVID-19 pandemic.
MD, MBA, DFASAM, DFAPA
Dr. Kelly J. Clark is the immediate past President Elect of ASAM. She currently chairs the Public Policy Council, consisting of the Legislative Advocacy, Payer Relations, and Public Policy Committees.
Board certified in addiction medicine and psychiatry, she has focused her career on issues of prescription drug abuse, evidence informed behavioral health care, and payment reform. Dr. Clark is Chief Medical Officer of CleanSlate Centers, a multi-state medical group currently treating over 5,000 opioid addicted patients with medication management, and which has received a SAMHSA Science to Service Award for Office Based Opioid Treatment. She is active on the Association of Managed Care Pharmacy's Addiction Treatment Advisory Group; served on the writing committee of the Johns Hopkins Bloomberg School of Public Health's recent policy document, “The Prescription Drug Epidemic: An Evidence Based Approach”; and led the workgroup on Health Systems and Reimbursement at SAMHSA's Buprenorphine Summit.
As the Behavioral Health Medical Director of CDPHP, a non-profit health plan in New York, she provided the clinical leadership for in-sourcing the management of behavioral health benefits. As Chief Medical Officer for Behavioral Health Group, she again focused on opioid addiction. Her expertise in payment models, quality metrics, medical-behavioral health integration, and clinical care delivery systems, as well as her clinical work treating people with addictive disease, all allow her to offer insights and recommendations to address the current epidemic.
As faculty of the University of Massachusetts Medical School for eight years, Dr. Clark trained students and resident physicians on addiction. She is currently a member of the American Psychiatric Association's Integrated Care Work Group; the National Rx Drug Abuse Summit Advisory Board; and the faculty of the Virginia Tech Carilion School of Medicine.
Margaret Jarvism MD, DFASAM finished her medical school, psychiatry residency and Addiction Medicine Fellowship at the Medical College of Virginia in Richmond. She is board certified and recertified in psychiatry with the CAQ in Addiction Psychiatry. She was ASAM certified (now ABAM certified). She has been a member of ASAM since the early 90’s and became a Fellow of the Society in 2003. She has served on the Board of Directors for one term and currently is the co-chair of the Ruth Fox Planning; and a member of the Finance Committee and the Constitution and Bylaws Committee. She has also worked on Examination Committee for ASAM and now ABAM since 2000.
Dr. Jarvis is the Medical Director at Marworth, in Waverly, PA, which is the residential addiction treatment center for the Geisinger Health System. She has been in this position since 1999. She is also Clinical Assistant Professor of Psychiatry at the Penn State University College of Medicine in Hershey, PA.
Dr. Jarvis is a member of the Society for the Advancement of Sexual Health, a professional organization of therapists who treat sexual addiction, and served on that board of directors from 2001-2006, as president from 2004-2006. She received the Merit award from SASH in 2011. Dr. Jarvis currently serves as the Treasurer of the Board of Marley’s Mission, a non-profit that provides equine-assisted psychotherapy to abused children in the Scranton, PA area.
Melissa B. Weimer
DO, MCR, FASAM
Melissa B. Weimer, DO, MCR, FASAM is board-certified in general internal medicine and addiction medicine and Assistant Professor of Medicine and Associate Program Director of the Addiction Medicine Fellowship at Yale University. She is an expert in hospital-based care for patients with substance use disorders and has worked with colleagues to develop successful hospital-based Addiction Medicine Consult Services at both Oregon Health & Science University and Yale University. Dr. Weimer is also a national leader in addiction medicine education and has developed curricula for safe opioid prescribing and addiction treatment through PCSS. Dr. Weimer serves of the national board of ASAM.
MD, MBA, FASA
Vincent Nelson, M.D., is vice president of Medical Affairs in the Office of Clinical Affairs (OCA) for the Blue Cross Blue Shield Association (BCBSA), a national federation of 36 independent, community-based and locally operated Blue Cross and Blue Shield (BCBS) companies. The BCBS System is the nation’s largest health insurer covering one in three Americans.
Dr. Nelson provides clinical leadership across multiples disciplines, including quality management, provider recognition, medical policy, innovations of service delivery and strategic market opportunities. He ensures that the OCA and BCBSA incorporate clinical guidance that aligns with market demand and positively impacts the quality of healthcare while maintaining BCBS System leadership with members, providers and stakeholders. Prior to BCBSA, Dr. Nelson was a senior medical director/market chief medical officer for the Central/West U.S. Region at United Healthcare, where he partnered with senior leadership teams to lead market level programs, integrate clinical functions and drive results for clinical affordability, quality and population health measures.
Previously, Dr. Nelson held the position of Assistant Professor in the Department of Anesthesiology, Critical Care, and Pain Medicine, at the University of Texas Health Science Center, McGovern Medical School in Houston, Texas. His interests and activities were in clinical care, teaching residents, and supporting department collaborations with industry sponsored pharmaceutical and medical device clinical trials. Before his careers in academia and industry, Dr. Nelson worked as a private practice clinician for 12½ years. He was a founding physician partner and board member of United States Anesthesia Partners (USAP).
Dr. Nelson obtained his bachelor’s degree in biological sciences from Stanford University. He holds a master’s degree in business administration from Rice University, Jones School of Business, and a medical degree from the University of Chicago, Pritzker School of Medicine. He completed his Clinical Residency and Fellowship training at Harvard Medical School, in the Department of Anesthesiology, Pain Management, and Critical Care Medicine at Massachusetts General Hospital, Boston, Mass.
Credits and Disclosures
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACCME Accreditation Statement
This activity has been planned and implemented in accordance with the essential areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The American Society of Addiction Medicine and The National Academy of Medicine (NAM). The American Society of Addiction Medicine is accredited by the ACCME to provide continuing medical education for physicians.
NAADAC, the Association for Addiction Professionals
This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.
California Association for Drug/Alcohol Educators (CAADE)
This educational program is approved by CAADE: #CP40 999 1222
California Association of DUI Treatment Centers (CADTP)
This educational program is approved by CADTP: #205
Continuing Education Credits (CEUs)
Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.
Maintenance of Certification
American Board of Preventive Medicine (ABPM)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.
American Board of Anesthesiology (ABA)
This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.
American Board of Pediatrics (ABP)
Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 1.5 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.
American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
American Board of Psychiatry and Neurology (ABPN)
Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.
American Board of Addiction Medicine (ABAM)
Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.
CME Reviewer and Disclosure Information
ASAM CME Committee Reviewer
The ASAM COVID-19 Review Team
Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information
In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
ACCME’s Policy For Disclosures During The COVID-19 Pandemic
Per ACCME’s simplified process for COVID-19, the requirement of disclosure of relevant financial relationships and resolution of personal conflicts of interest has been removed. Currently, there are no FDA-approved vaccines or treatments for COVID-19. Hence, there is no possibility of a relevant financial relationship that would create a conflict of interest.
Faculty and Panelists
Kelly J. Clark, MD, MBA
Immediate Past President, American Society of Addiction Medicine
Elizabeth Finkelman, MPP
Director, Action Collaborative on Countering the U.S. Opioid Epidemic, National Academy of Medicine
Brian Hurley, MD, MBA
Director of Addiction Medicine, Los Angeles County Department of Health Services
Chris Bundy, MD, MPH
Executive Medical Director, Washington Physicians Health Program
Cortney Lovell, CRPA, CARC, RCP
Recovery Coach and Co-Founder, Our Wellness Collective
|Access Date||Quiz Result||Score||Actions|